Drug – bio-affecting and body treating compositions – Antigen – epitope – or other immunospecific immunoeffector – Conjugate or complex
Patent
1997-02-10
1998-04-14
Witz, Jean C.
Drug, bio-affecting and body treating compositions
Antigen, epitope, or other immunospecific immunoeffector
Conjugate or complex
514934, 514925, 514861, 514886, A61K 3578
Patent
active
057388504
DESCRIPTION:
BRIEF SUMMARY
FIELD OF INVENTION
The invention relates to a phytotherapeutic agent for the treatment of skin lesions and morbid changes in the skin and methods for its preparation.
BACKGROUND INFORMATION AND PRIOR ART
It is well known that herpes simplex is a pantropic, facultative neurotropic virus disease due to a primary infection with herpes simplex viruses (HSV 1 or 2) or by reactivating viruses persisting in ganglia. The incubation time in the case of a primary infection is 2 to 7 days; transmission: after the maternal antibody protection has subsided, the first infections occurs mostly in young children due to smear and droplet infections from herpes lesions or from healthy permanent carriers. A herpes infection does not confer lifelong immunity. Relapses can occur due to irritation of latent infected neurons after feverish infections, isolation, menstruation, traumas and gastrointestinal disorders, but also due to immunosuppression and hormonal or physical factors. The symptoms are itching and a sensation of tenseness, then grouped vesicles on a reddened background, which dry out to crusts and heal without scars after 8 to 10 days; regional lymph nodes frequently are slightly swollen and painful. Herpes simplex can recur at regular intervals, possibly also always at the same site. The location usually is in the region of the lips, the vulva or the penis and also in the face.
The presently known therapeutic agents and remedies have some disadvantages; this is true for the known organic or inorganic chemotherapeutic agents, as well as for the known phytotherapeutic agents. Creams, gels, solutions and powders are offered, some of which contain plant components, such as extracts of balm leaves, echinacea, chamomile, arnica, etc. or pharmaceutically active organic chemicals, such as benzocaine, sulfonamides, tetracaine, allantoin, vidarabin, acyclovir, ribavivirin, didesoxycytidine, azidothymidine or inorganic chemicals, such as elemental sulfur, insoluble mercury salts and soluble mercury salts in homeopathic concentrations.
The known phytotherapeutic agents have only a slight healing action and are limited to an accompanying effect of the self-healing. Some of the chemotherapeutic agents have considerable side effects on cells, which are not infected, and frequently are the cause of allergic reactions. In addition, their frequent use produces mutants, so that, after some time, the chemotherapeutic agent loses its main effect and is left only with the unwanted, harmful side effects. For example, the agents, which contain acyclovir as active ingredient, must be discontinued after a 10-day use.
No agent can prevent re-infections or relapses. In view of the possibility of a herpes encephalitis infection, this is particularly serious. Most agents contain preservatives, which are also cytotoxic for eukaryotes. For this reason, latent viruses, which are present as provirus in the host cell, are provoked to reproduce the virus actively. The infection is intensified. Very few of the agents ameliorate pain; only those agents, which contain local anesthetics, such as benzocaine, form an exception. The cosmetic effect of known agents generally is very disadvantageous.
OBJECT OF THE INVENTION
The basic object of the invention therefore is to make available a therapeutic agent against herpes simplex, the main therapeutic effect of which is comparatively more pronounced. At the same time, unwanted side effects are to be minimal and negligible. Moreover, the therapeutic agent shall ameliorate pain, itching and a sensation of tenseness, resulting from the herpes simplex, and be cosmetically unobtrusive. Furthermore, it is an object of the invention to make available a therapeutic agent, which is generally suitable for the treatment of skin lesions and morbid skin changes.
SUMMARY OF THE INVENTION
Pursuant to the invention, this objective is accomplished with a phytotherapeutic agent of claim 1.
It has turned out that a topical treatment of the vesicles, which occur as a result of the infection, as well as of the adjacent
REFERENCES:
patent: 4469685 (1984-09-01), Kojima et al.
patent: 5061491 (1991-10-01), Deryabin
The New England Journal of Medecine, 303, No. 10, 583 (Jul. 3, 1980).
Hendricks Horst Walter
Hendricks Sabine
LandOfFree
Therapeutic composition for the treatment of skin lesions and me does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Therapeutic composition for the treatment of skin lesions and me, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Therapeutic composition for the treatment of skin lesions and me will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-632636